7-oxo-DHEA and Raynaud's phenomenon

Medical Hypotheses

Volumn 60, Issue 3, 2003, Pages 391-397

  Ihler, Garret ^a   Chami Stemmann, Hasna ^a,b  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA ACETOXYANDROST 5 ENE 7,17 DIONE; ADENOSINE TRIPHOSPHATE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; GLUCOSE; LEVOTHYROXINE; LIOTHYRONINE; METFORMIN; NIFEDIPINE; NITRATE; PLACEBO; PROSTAGLANDIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SEROTONIN ANTAGONIST; STEROID; THROMBOXANE SYNTHASE; THYROID HORMONE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3; VASODILATOR AGENT;

ACUPUNCTURE; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; EDEMA; FEEDBACK SYSTEM; FLUSHING; GLUCONEOGENESIS; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HORNER SYNDROME; HUMAN; HYPOTHYROIDISM; MICROCIRCULATION; MUSCLE WEAKNESS; NONHUMAN; PATIENT EDUCATION; PERIPHERAL VASCULAR DISEASE; PLEURA EFFUSION; PNEUMOTHORAX; PRIORITY JOURNAL; RAT; RAYNAUD PHENOMENON; RELAXATION TRAINING; SIDE EFFECT; STEROID THERAPY; STRESS; SYMPATHECTOMY; SYMPTOMATOLOGY; SYNCOPE; TACHYCARDIA; THERMOGENESIS; VASOCONSTRICTION; VASOSPASM;

EID: 0037372696     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00409-7     Document Type: Article

References (54)

1. Riera G., Vilardell M., Vaque J., Fonollosa V., Bermejo B. Prevalence of Raynaud's phenomenon in a healthy Spanish population. J Rheumatol 1993; 20(1): 66-69.
2. Maricq H. R., Carpentier P. H., Weinrich M. C., Keil J. E., Palesch Y., Biro C., Vionnet-Fuasset M., Jiguet M., Valter I. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol 1997; 24(5): 879-889.
3. Coffman J. D. The diagnosis of Raynaud's phenomenon. Clin Dermatol 1994; 12: 283-289.
4. Coffman J. D. Raynaud's Phenomenon. New York: Oxford University Press, 1989.
5. Planchon B., Pitorius M., Beurrier P. et al. Primary Raynaud's Phenomenon: age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45: 677-686.
6. Freedman R. R., Mayes M. D. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996; 39: 1189-1191.
7. Fraenkel L., Zhang Y., Chaisson C. E., Maricq H. R., Evans S. R., Brand F., Wilson P. W., Felson D. T. Different factors influencing the expression of Raynaud's phenomenon in men and women. Arthritis Rheum 1999; 42(2): 306-310.
8. Lawlor Smith L., Lawlor Smith C. Vasospasm of nipple - a manifestation of Raynaud's phenomenon: case reports. Br Med 1997; 314: 644-645.
9. Maricq H. R., Carpentier P. H., Weinrich M. C., Keil J. E., Franco A., Drouet P., Poncot O. C., Maines M. V. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol 1993; 20(1): 70-76.
10. Melin B., Sandqvist D. Effect of thematically relevant visual stimuli in Raynaud's disease. Scand J Behav Ther 1994; 23: 53-60.
11. Surwit R. S. Behavior treatment of Raynaud's Syndrom in peripheral vascular disease. J Consult Clin Psycol 1982; 50: 922-933.
12. Appiah R., Hiller S., Caspary L., Alexander K., Creutzig A. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med 1997; 241(2): 119-124.
13. Cerinic M. M., Generini S., Pignone A. A new approaches to the treatment of Raynaud's phenomenon. Curr Open Rheumatol 1997; 9: 544-556.
14. Belch J. J. F., Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs 1996; 52: 682-695.
15. Teh L. S., Manning J., Moore T., Tully M. P., O'Reilly D., Jayson M. I. V. Sustained-release transdermal glyceryl trinitrate patches as treatment for primary and secondary Raynaud' phenomenon. Br J Rheumatol 1995; 34: 636-641.
16. Tucker A. T., Pearson R. M., Cooke E. D., Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial. Lancet 1999; 354: 1670-1675.
17. Johnston E. N. M., Summerly R., Birnstingl M. Prognosis in Raynaud's phenomenon after sympathoectomy. Br Mrd J 1965; 1: 962-964.
18. Janoff K. A., Phinney E. S., Porter J. M. Lumbar sympathectomy for lower extremity vasospasm. Am J Surg 1985; 150: 147-152.
19. Peacock J. H. The treatment of primary Raynaud's disease of the upper limb. Lancet 1960; 2: 65-69.
20. Dessein P. H., Gledhill R. F. Treatment of Raynaud's phenomenon with large doses of triiodothyronine: a pilot study. Ann Rheum Dis 1987; 46(12): 944-945.
21. Dessein P. H., Gledhill R. F. Tri-iodothyronine in Raynaud's phenomenon: further objective evidence of its beneficial effect. Br J Rheumatol 1988; 27(3): 244-246.
22. Lateiwish A. M., Feher J., Baraczka K., Racz K., Kiss R., Glaz E. Remission of Raynaud's phenomenon after L-thyroxine therapy in a patient with hypothyroidism. J Endocrinol Invest 1992; 15(1): 49-51.
23. Shagan B. P., Friedman S. A. Raynaud's phenomenon in hypothyroidism. Angiology 1976; 27(1): 19-25.
24. Shagan B. P., Friedman S. A. Raynaud's phenomenon and thyroid deficiency. Arch Intern Med 1980; 140(6): 832-833.
25. Kontos H. A. Vascular diseases of the limbs. In: J. C. Bennett, F. Plum (eds). Cecil Textbook of Medicine, 20th Edn. Philadelphia: W.B. Saunders, 1996: 349.
26. Dessein P. H., Morrison R. C., Lamparelli R. D., van der Merwe C. A. Triiodothyronine treatment for Raynaud's phenomenon: a controlled trial. J Rheumatol 1990; 17(8): 1025-1028.
27. Nielsen S. L., Parving H. H., Hansen J. E. Myxoedema and Raynaud's phenomenon (Copenh). Acta Endocrinol 1982; 101(1): 32-34.
28. Grassi W., De Angelis R., Lapadula G., Leardini G., Scarpa R. Clinical diagnosis found in patients with Raynaud's phenomenon: a multicentre study. Rheumatol Int 1998; 18(1): 17-20.
29. Rupp P. A., Mellinger S., Kohler J., Dorsey J. K., Furst D. E. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker. J Rheumatol 1987; 14(4): 745-750.
30. Kahan A., Amor B., Menkes C. J. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 1985; 44(1): 30-33.
31. Lebon V., Dufour S., Petersen K. F., Ren J., Jucker B. M., Slezak L. A., Cline G. W., Rothman D. L., Shulman G. I. Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle. J Clin Invest 2001; 108(5): 733-737.
32. Young A. J., Castellani J. W. Exertion-induced fatigue and thermoregulation in the cold. Comp Biochem Physiol A Mol Integr Physiol 2001; 128(4): 769-776.
33. Sendowski I., Savourey G., Launay J. C., Besnard Y., Cottet-Emard J. M., Pequignot J. M., Bittel J. Sympathetic stimulation induced by hand cooling alters cold-induced vasodilatation in humans. Eur J Appl Physiol 2000; 81(4): 303-309.
34. Krogstad A. L., Elam M., Karlsson T., Wallin B. G. Arteriovenous anastomoses and the thermoregulatory shift between cutaneous vasoconstrictor and vasodilator reflexes. J Auton Nerv Syst 1995; 53(2-3): 215-222.
35. Toms S. L., Cooke E. D. A comparison of the functioning of arteriovenous anastomoses in secondary Raynaud's phenomenon and control subjects in response to local hand warming. Int Angiol 1995; 14(1): 74-79.
36. Eyolfson D. A., Tikuisis P., Xu X., Weseen G., Giesbrecht G. G. Measurement and prediction of peak shivering intensity in humans. Eur J Appl Physiol 2001; 84(1-2): 100-106.
37. de Jesus L. A., Carvalho S. D., Ribeiro M. O., Schneider M., Kim S. W., Harney J. W., Larsen P. R., Bianco A. C. The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J Clin Invest 2001; 108(9): 1379-1385.
38. Coleman D. L., Schwizer R. W., Leiter E. H. Effect of genetic background on the therapeutic effects of dehydroepiandrosterone (DHEA) in diabetes-obesity mutants and in aged normal mice. Diabetes 1984; 33(1): 26-32.
39. Tagliaferro A. R., Davis J. R., Truchon S., Van Hamont N. Effects of dehydroepiandrosterone acetate on metabolism, body weight and composition of male and female rats. J Nutr 1986; 116(10): 1977-1983.
40. Marwah P., Marwah A., Kneer N., Lardy H. Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates. Steroids 2001; 66(7): 581-595.
41. Lardy H., Partridge B., Kneer N., Wei Y. Ergosteroids: induction of thermogenic enzymes in liver of rats treated with steroids derived from dehydroepiandrosterone. Proc Natl Acad Sci USA 1995; 92(14): 6617-6619.
42. McIntosh M. K., Berdanier C. D. Antiobesity effects of dehydroepiandrosterone are mediated by futile substrate cycling in hepatocytes of BHE/cdb rats. J Nutr 1991; 121(12): 2037-2043.
43. Song M. K., Grieco D., Rall J. E., Nikodem V. M. Thyroid hormone-mediated transcriptional activation of the rat liver malic enzyme gene by dehydroepiandrosterone. J Biol Chem 1989; 264(32): 18981-18985.
44. Bobyleva V., Bellei M., Kneer N., Lardy H. The effects of the ergosteroid 7-oxo-dehydroepiandrosterone on mitochondrial membrane potential: possible relationship to thermogenesis. Arch Biochem Biophys 1997; 341(1): 122-128.
45. Golozoubova V., Hohtola E., Matthias A., Jacobsson A., Cannon B., Nedergaard J. Only UCP1 can mediate adaptive nonshivering thermogenesis in the cold. FASEB J 2001; 15(11): 2048-2050.
46. Barbe P., Larrouy D., Boulanger C., Chevillotte E., Viguerie N., Thalamas C., Trastoy M. O., Roques M., Vidal H., Langin D. Triiodothyronine-mediated up-regulation of UCP2 and UCP3 mRNA expression in human skeletal muscle without coordinated induction of mitochondrial respiratory chain genes. FASEB J 2001; 15(1): 13-15.
47. Soumano K., Desbiens S., Rabelo R., Bakopanos E., Camirand A., Silva J. E. Glucocorticoids inhibit the transcriptional response of the uncoupling protein-1 gene to adrenergic stimulation in a brown adipose cell line. Mol Cell Endocrinol 2000; 165(1-2): 7-15.
48. Hampl R., Lapcik O., Hill M., Klak J., Kasal A., Novacek A., Sterzl I., Sterzl J., Starka L. 7-Hydroxydehydroepiandrosterone - a natural antiglucocorticoid and a candidate for steroid replacement therapy?. Physiol Res 2000; 49(Suppl 1): S107-S112.
49. Owen M. R., Doran E., Halestrap A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348(Pt 3): 607-614.
50. El-Mir M. Y., Nogueira V., Fontaine E., Averet N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275(1): 223-228.
51. Davidson M., Marwah A., Sawchuk R. J., Maki K., Marwah P., Weeks C., Lardy H. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin Invest Med 2000; 23(5): 300-310.
52. Lardy H., Kneer N., Wei Y., Partridge B., Marwah P. Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone. Steroids 1998; 63(3): 158-165.
53. Henwood S. M., Weeks C. E., Lardy H. An escalating dose oral gavage study of 3beta-acetoxyandrost-5-ene-7, 17-dione (7-oxo-DHEA-acetate) in rhesus monkeys. Biochem Biophys Res Commun 1999; 254(1): 124-126.
54. Lardy H., Henwood S. M., Weeks C. E. An acute oral gavage study of 3-β-acetoxyandrost-5-ene-7,17-dione (7-oxo-DHEA-acetate) in rats. Biochem Biophys Res Commun 1999; 254(1): 120-123.